Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Selective Targeting of Virus Replication by Proton Pump Inhibitors.

Watanabe SM, Ehrlich LS, Strickland M, Li X, Soloveva V, Goff AJ, Stauft CB, Bhaduri-McIntosh S, Tjandra N, Carter C.

Sci Rep. 2020 Mar 4;10(1):4003. doi: 10.1038/s41598-020-60544-y.

2.

Tsg101 chaperone function revealed by HIV-1 assembly inhibitors.

Strickland M, Ehrlich LS, Watanabe S, Khan M, Strub MP, Luan CH, Powell MD, Leis J, Tjandra N, Carter CA.

Nat Commun. 2017 Nov 9;8(1):1391. doi: 10.1038/s41467-017-01426-2.

3.

Tsg101 regulates PI(4,5)P2/Ca(2+) signaling for HIV-1 Gag assembly.

Ehrlich LS, Medina GN, Photiadis S, Whittredge PB, Watanabe S, Taraska JW, Carter CA.

Front Microbiol. 2014 May 20;5:234. doi: 10.3389/fmicb.2014.00234. eCollection 2014.

4.

HIV Assembly and Budding: Ca(2+) Signaling and Non-ESCRT Proteins Set the Stage.

Ehrlich LS, Carter CA.

Mol Biol Int. 2012;2012:851670. doi: 10.1155/2012/851670. Epub 2012 Jun 12.

5.

ESCRT machinery potentiates HIV-1 utilization of the PI(4,5)P(2)-PLC-IP3R-Ca(2+) signaling cascade.

Ehrlich LS, Medina GN, Carter CA.

J Mol Biol. 2011 Oct 21;413(2):347-58. doi: 10.1016/j.jmb.2011.08.038. Epub 2011 Aug 22.

6.

Sprouty2 regulates PI(4,5)P2/Ca2+ signaling and HIV-1 Gag release.

Ehrlich LS, Medina GN, Carter CA.

J Mol Biol. 2011 Jul 22;410(4):716-25. doi: 10.1016/j.jmb.2011.04.069.

7.

Sprouty 2 binds ESCRT-II factor Eap20 and facilitates HIV-1 gag release.

Medina GN, Ehrlich LS, Chen MH, Khan MB, Powell MD, Carter CA.

J Virol. 2011 Jul;85(14):7353-62. doi: 10.1128/JVI.00141-11. Epub 2011 May 4.

8.

Phosphoinositides direct equine infectious anemia virus gag trafficking and release.

Fernandes F, Chen K, Ehrlich LS, Jin J, Chen MH, Medina GN, Symons M, Montelaro R, Donaldson J, Tjandra N, Carter CA.

Traffic. 2011 Apr;12(4):438-51. doi: 10.1111/j.1600-0854.2010.01153.x. Epub 2011 Feb 1.

9.

Activation of the inositol (1,4,5)-triphosphate calcium gate receptor is required for HIV-1 Gag release.

Ehrlich LS, Medina GN, Khan MB, Powell MD, Mikoshiba K, Carter CA.

J Virol. 2010 Jul;84(13):6438-51. doi: 10.1128/JVI.01588-09. Epub 2010 Apr 28.

10.

Cell biology of HIV-1 infection of macrophages.

Carter CA, Ehrlich LS.

Annu Rev Microbiol. 2008;62:425-43. doi: 10.1146/annurev.micro.62.081307.162758. Review.

PMID:
18785842
11.

Tsg101 can replace Nedd4 function in ASV Gag release but not membrane targeting.

Medina G, Pincetic A, Ehrlich LS, Zhang Y, Tang Y, Leis J, Carter CA.

Virology. 2008 Jul 20;377(1):30-8. doi: 10.1016/j.virol.2008.04.024.

12.

Tsg101 control of human immunodeficiency virus type 1 Gag trafficking and release.

Goff A, Ehrlich LS, Cohen SN, Carter CA.

J Virol. 2003 Sep;77(17):9173-82.

13.

HIV-1 capsid protein forms spherical (immature-like) and tubular (mature-like) particles in vitro: structure switching by pH-induced conformational changes.

Ehrlich LS, Liu T, Scarlata S, Chu B, Carter CA.

Biophys J. 2001 Jul;81(1):586-94. Erratum in: Biophys J 2001 Nov;81(5):2992.

14.

Structural consequences of cyclophilin A binding on maturational refolding in human immunodeficiency virus type 1 capsid protein.

Dietrich L, Ehrlich LS, LaGrassa TJ, Ebbets-Reed D, Carter C.

J Virol. 2001 May;75(10):4721-33.

15.

Membrane-induced alterations in HIV-1 Gag and matrix protein-protein interactions.

Scarlata S, Ehrlich LS, Carter CA.

J Mol Biol. 1998 Mar 27;277(2):161-9.

PMID:
9514761
16.

Crystal structure of dimeric HIV-1 capsid protein.

Momany C, Kovari LC, Prongay AJ, Keller W, Gitti RK, Lee BM, Gorbalenya AE, Tong L, McClure J, Ehrlich LS, Summers MF, Carter C, Rossmann MG.

Nat Struct Biol. 1996 Sep;3(9):763-70.

PMID:
8784350
17.

Partitioning of HIV-1 Gag and Gag-related proteins to membranes.

Ehrlich LS, Fong S, Scarlata S, Zybarth G, Carter C.

Biochemistry. 1996 Apr 2;35(13):3933-43.

PMID:
8672424
18.

A preliminary evaluation of hydroxyurea for the treatment of rheumatoid arthritis.

Ehrlich LS, Thalji K, Whitman K, Albert DA.

J Rheumatol. 1995 Sep;22(9):1646-50.

PMID:
8523337
19.

Spectral analysis and tryptic susceptibility as probes of HIV-1 capsid protein structure.

Ehrlich LS, Agresta BE, Gelfand CA, Jentoft J, Carter CA.

Virology. 1994 Nov 1;204(2):515-25.

PMID:
7941318
20.

Transformation of NIH/3T3 to anchorage independence by H-ras is accompanied by loss of suppressor activity.

Tolsma SS, Cohen JD, Ehrlich LS, Bouck NP.

Exp Cell Res. 1993 Apr;205(2):232-9.

PMID:
8482334
21.

Inactivation of the human immunodeficiency virus by hypericin: evidence for photochemical alterations of p24 and a block in uncoating.

Degar S, Prince AM, Pascual D, Lavie G, Levin B, Mazur Y, Lavie D, Ehrlich LS, Carter C, Meruelo D.

AIDS Res Hum Retroviruses. 1992 Nov;8(11):1929-36.

PMID:
1283309
22.

Assembly of recombinant human immunodeficiency virus type 1 capsid protein in vitro.

Ehrlich LS, Agresta BE, Carter CA.

J Virol. 1992 Aug;66(8):4874-83.

23.

Preparation and crystallization of a human immunodeficiency virus p24-Fab complex.

Prongay AJ, Smith TJ, Rossmann MG, Ehrlich LS, Carter CA, McClure J.

Proc Natl Acad Sci U S A. 1990 Dec;87(24):9980-4.

24.

Expression in Escherichia coli and purification of human immunodeficiency virus type 1 capsid protein (p24).

Ehrlich LS, Krausslich HG, Wimmer E, Carter CA.

AIDS Res Hum Retroviruses. 1990 Oct;6(10):1169-75.

PMID:
2123631

Supplemental Content

Loading ...
Support Center